Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?

The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for the treatment of refractory chronic lymphocytic Leukemia (CLL). A key... Author: VJHemOnc Added: 08/07/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts